Delivering Canada's first cutting-edge cell and gene therapy facility

The OmniaBio B ultra fast-tracked project is accommodating the largest cell and gene therapy Contract Development & Manufacturing Organization (CDMO) in Canada producing gene-modified and viral vectors in Hamilton, Ontario. 

OmniaBio B is an Integrated Project Delivery (IPD) contract to deliver the project for McMaster Innovation Park (MIP) and their tenant OmniaBio.

Multiplex will deliver the core and shell as part of the first phase of the project that when completed, will span 119,000 square feet over three storeys. Its final design will feature clean rooms, specialized labs, offices and Current Good Manufacturing Practice (cGMP) compliant manufacturing.